Bioanalytical Systems, Inc. : Jacqueline Lemke Named Interim President & CEO of Bioanalytical Systems
07/06/2012| 08:05am US/Eastern
Recommend:
BASi (Bioanalytical Systems, Inc.) (NASDAQ:BASI) announced today that
CFO Jacqueline M. Lemke has been named to the additional posts of
interim President & CEO. Ms. Lemke succeeds Anthony S. Chilton, Ph.D.,
who has resigned as CEO to pursue other opportunities.
"Jacqueline Lemke has demonstrated exceptional skill, energy and
commitment since she joined BASi as CFO three months ago. In this short
time she has significantly reduced the company's cost structure,
refocused our marketing program, and instituted aggressive performance
goals for all operating departments. Many more changes are in the works.
As interim President and CEO, with continuing responsibility as CFO, we
expect Jackie to complete the transformation of BASi and deliver the
growth and profitability we believe this company is capable of
delivering. Board member Richard Johnson and I, with more than 60 years
of combined major pharma and CRO experience, will work closely with
Jackie during this interim period," said John B. Landis, Ph.D., Chairman.
"BASi has provided drug development and discovery services to the
pharmaceutical industry for more than 35 years. We have a superb and
dedicated technical staff, world-class laboratory facilities, and we
enjoy an outstanding reputation for the quality of our services and
proprietary test instruments. With these critical building blocks in
place, I believe we can improve the company's operating performance and
restore revenue growth, and I am committed to making this happen," Ms.
Lemke said.
Ms. Lemke has more than 20 years of experience in critical financial
reporting and management positions, most recently as Vice President of
Finance and Global CFO of Remy, Inc., a $900 million division of Remy
International, where she built a 44-person global finance team and
created a financial system to support rapid decision making and clear
lines of management accountability. Earlier, she served as Vice
President of Finance, Global CFO Connected Home Solutions at Motorola,
Inc., and was Strategic Planning Director, Global Invista division at
DuPont. Ms. Lemke is a CPA and began her career as a tax consultant at
Deloitte Touche.
BASi also announced the resignation of Alberto Hidalgo, Vice President,
Business Development and Marketing.
About BASi
BASi is a drug discovery and development services company providing
contract research services and instruments to the world's leading
pharmaceutical companies and medical research organizations. The
company, based in the Purdue Research Park, focuses on developing
innovative services and products that increase efficiency and reduce the
cost of taking new and generic drugs to market. Visit www.BASInc.com
for more about BASi.
Safe Harbor Statement
This release contains forward-looking statements that are subject to
risks and uncertainties including, but not limited to, risks and
uncertainties related to changes in the market and demand for our
products and services, the development, marketing and sales of products
and services, changes in technology, industry standards and regulatory
standards, and various market and operating risks detailed in the
company's filings with the Securities and Exchange Commission.
BASi
Sue Scott
Marketing Communications Manager
765-497-8458
sscott@basinc.com
or
Berkman
Associates
Neil Berkman
Investor Relations
310-477-3118
info@berkmanassociates.com
© Business Wire 2012
Recommend :
